Venetoclax has now been approved in combination with hypomethylating agents by the United States Food and Drug Administration (FDA) [131], and targeted therapies, such as IDH1/2 inhibitors, have been effectively used in high-risk MDS and AML-MRC patients with IDH1/2 mutations [131]. This evidence concerns the gene IDH1 and acute myeloid leukemia.